The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder in addition to continued development on other programs within its clinical-stage precision psychiatry pipeline. Proceeds from the financing will also be used to progress the company's artificial intelligence-enabled brain biomarker platform and launch new clinical trials in areas of high unmet medical need. Alto will report Phase 2a data in early 2023 and further anticipates Phase 2b data readouts by early 2024.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

369 South San Antonio Rd.
Los Altos, CA 94022
USA

Phone

Undisclosed

Website

www.altoneuroscience.com

Email Address

[email protected]

Overview

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions.

Profile

Social Media

Alto Neuroscience Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Amit Etkin

Chief Medical Officer

Adam Savitz

Chief Operating Officer

Daniel Segal

Co-Founder

Wei Wu

Vice President

Bruce Morimoto

VP - Bus. Development

Nick Smith

VP - Operations

Lesley Parker

Browse more venture capital transactions:

Prev: 10/25/2022: Bilt Rewards venture capital transaction
Next: 10/25/2022: AM Batteries venture capital transaction

Share this article

Where The Data Comes From

We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary